Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant in a Nursing Home 28 weeks after two doses of mRNA anti-Covid-19 vaccines: evidence of a waning immunity

Alice Pierobon, Alessandra Dal Zotto, Antonio Antico, De Antoni Mario Ernesto, Liviano Vianello, Monica Gennari, Antonio Di Caprio, Francesca Russo, View ORCID ProfileGianfranco Brambilla, Mario Saugo
doi: https://doi.org/10.1101/2021.10.25.21265370
Alice Pierobon
1Dipartimento di Prevenzione ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessandra Dal Zotto
1Dipartimento di Prevenzione ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Antico
2UOC Laboratorio Analisi ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
De Antoni Mario Ernesto
3Casa di Riposo di Cartigliano
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liviano Vianello
1Dipartimento di Prevenzione ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Gennari
1Dipartimento di Prevenzione ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Di Caprio
4Direzione Sanitaria ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Russo
5Direzione Regionale Prevenzione Regione del Veneto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gianfranco Brambilla
6Istituto Superiore di Sanità
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gianfranco Brambilla
Mario Saugo
1Dipartimento di Prevenzione ULSS 7
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mario.saugo@aulss7.veneto.it
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Objectives Description of a SARS-CoV-2 B.1.617.2 (Delta) variant outbreak among residents (N=69) and Health Workers (HWs: N=69) of a small Nursing Home in Northern-East Italy, with full vaccination coverage of 91 and 82%, respectively. Evaluation of the Anti-Spike IgG titers 28 weeks after the mRNA vaccine boosts against SARS-COV-2 infection and severe Covid-19.

Materials and methods A timely collection of sera within 48h from the index case; anti-Spike IgG determination (expressed as Binding Antibody Units – BAU/mL) through a commercial quantitative assay; SARS-CoV-2 diagnostics via RT-PCR, and full-genome sequencing for lineage characterization. Residents were grouped according to anti-Spike IgG titers (≤ 50, 51-1000, and > 1000 BAU/mL) and resulting protection against the infection and the severe disease was measured.

Results 0/20 HWs and 14/59 (24%) residents fully vaccinated and without a previous SARS-CoV-2 infection showed anti-Spike IgG lower/equal to 50 BAU/mL (1-sided Fisher exact p=0.011). Among these residents, a level of anti-Spike IgG ≤50 BAU/mL resulted in a higher risk of SARS-CoV-2 infection (RR=1.55, CI95% 1.17-2.05) and severe Covid-19 disease (RR=5.33, CI95% 1.83-15.57). Conclusion Low levels of SARS-CoV-2 neutralizing anti-Spike IgG in serum 28 weeks after the administration of the second dose parallels the waning of vaccine protection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the competent ULSS 7 Bassano del Grappa (VI, Italy) Ethics Committee on Aug 26, 2021.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript. https://www.gisaid.org/; ID numbers: EPI_ISL_4556244; EPI_ISL_4556245; EPI_ISL_4556247; EPI_ISL_4556248; EPI_ISL_4556250; EPI_ISL_4556252; EPI_ISL_4556253; EPI_ISL_4556256; EPI_ISL_4556257, EPI_ISL_4556258.

https://www.gisaid.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 26, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant in a Nursing Home 28 weeks after two doses of mRNA anti-Covid-19 vaccines: evidence of a waning immunity
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant in a Nursing Home 28 weeks after two doses of mRNA anti-Covid-19 vaccines: evidence of a waning immunity
Alice Pierobon, Alessandra Dal Zotto, Antonio Antico, De Antoni Mario Ernesto, Liviano Vianello, Monica Gennari, Antonio Di Caprio, Francesca Russo, Gianfranco Brambilla, Mario Saugo
medRxiv 2021.10.25.21265370; doi: https://doi.org/10.1101/2021.10.25.21265370
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Outbreak of SARS-CoV-2 B.1.617.2 (Delta) variant in a Nursing Home 28 weeks after two doses of mRNA anti-Covid-19 vaccines: evidence of a waning immunity
Alice Pierobon, Alessandra Dal Zotto, Antonio Antico, De Antoni Mario Ernesto, Liviano Vianello, Monica Gennari, Antonio Di Caprio, Francesca Russo, Gianfranco Brambilla, Mario Saugo
medRxiv 2021.10.25.21265370; doi: https://doi.org/10.1101/2021.10.25.21265370

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1093)
  • Dentistry and Oral Medicine (195)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (499)
  • Epidemiology (9757)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2303)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1553)
  • Health Policy (732)
  • Health Systems and Quality Improvement (602)
  • Hematology (236)
  • HIV/AIDS (501)
  • Infectious Diseases (except HIV/AIDS) (11631)
  • Intensive Care and Critical Care Medicine (616)
  • Medical Education (236)
  • Medical Ethics (67)
  • Nephrology (256)
  • Neurology (2139)
  • Nursing (134)
  • Nutrition (335)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1172)
  • Ophthalmology (363)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (145)
  • Palliative Medicine (50)
  • Pathology (309)
  • Pediatrics (694)
  • Pharmacology and Therapeutics (298)
  • Primary Care Research (265)
  • Psychiatry and Clinical Psychology (2172)
  • Public and Global Health (4645)
  • Radiology and Imaging (775)
  • Rehabilitation Medicine and Physical Therapy (455)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (208)
  • Surgery (250)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)